Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariaelena Capone

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibitionRobert Ferguson, Vylyny Chat, Leah Morales, et al.
Cancer Immunology, Immunotherapy : CII|July 31, 2023
Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular trapsLuca Modestino, Leonardo Cristinziano, Marialuisa Trocchia, et al.
Cancer Immunology Research|December 7, 2017
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic MelanomaJeffrey S Weber, Mario Sznol, Ryan J Sullivan, et al.
Journal of Translational Medicine|March 13, 2020
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patientsMariaelena Capone, Federica Fratangelo, Diana Giannarelli, et al.
Journal of Translational Medicine|August 18, 2010
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatmentPaolo A Ascierto, Maria Napolitano, Egidio Celentano, et al.
Cancers|August 27, 2021
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, ItalyGabriele Madonna, Giuseppe V Masucci, Mariaelena Capone, et al.
Frontiers in Oncology|February 27, 2023
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative studyPaolo A Ascierto, Eleonora Cioli, Vanna Chiarion-Sileni, et al.
Cancer Letters|November 14, 2008
NEMO-binding domain peptide inhibits proliferation of human melanoma cellsAngela Ianaro, Mariaroberta Tersigni, Giuseppe Belardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, et al.
Oncoimmunology|July 9, 2015
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapyNicola Mozzillo, Ester Simeone, Lucia Benedetto, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibitionRobert Ferguson, Vylyny Chat, Leah Morales, et al.
Cancer Immunology, Immunotherapy : CII|July 31, 2023
Melanoma-derived soluble mediators modulate neutrophil biological properties and the release of neutrophil extracellular trapsLuca Modestino, Leonardo Cristinziano, Marialuisa Trocchia, et al.
Cancer Immunology Research|December 7, 2017
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic MelanomaJeffrey S Weber, Mario Sznol, Ryan J Sullivan, et al.
Journal of Translational Medicine|March 13, 2020
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patientsMariaelena Capone, Federica Fratangelo, Diana Giannarelli, et al.
Journal of Translational Medicine|August 18, 2010
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatmentPaolo A Ascierto, Maria Napolitano, Egidio Celentano, et al.
Cancers|August 27, 2021
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, ItalyGabriele Madonna, Giuseppe V Masucci, Mariaelena Capone, et al.
Frontiers in Oncology|February 27, 2023
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative studyPaolo A Ascierto, Eleonora Cioli, Vanna Chiarion-Sileni, et al.
Cancer Letters|November 14, 2008
NEMO-binding domain peptide inhibits proliferation of human melanoma cellsAngela Ianaro, Mariaroberta Tersigni, Giuseppe Belardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, et al.
Oncoimmunology|July 9, 2015
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapyNicola Mozzillo, Ester Simeone, Lucia Benedetto, et al.
Pageof 7